Research Article

Combined Analysis of Endothelial, Hematopoietic, and Mesenchymal Stem Cell Compartments Shows Simultaneous but Independent Effects of Age and Heart Disease

Carine Ghem,1 Lucinara Dadda Dias,1 Roberto Tofani Sant’Anna,1 Renato A. K. Kalil,1,2 Melissa Markoski,1 and Nance Beyer Nardi1,3

1Institute of Cardiology of Rio Grande do Sul, Fundação Universitária de Cardiologia, Av. Princesa Isabel 395, 90040-371 Porto Alegre, RS, Brazil
2Universidade Federal de Ciências da Saúde de Porto Alegre, Rua Sarmento Leite 245, 90050-170 Porto Alegre, RS, Brazil
3Laboratory of Stem Cells and Tissue Engineering, Universidade Luterana do Brasil, Av. Farroupilha 8001, 92425-900 Canoas, RS, Brazil

Correspondence should be addressed to Nance Beyer Nardi; nancenardi@gmail.com

Received 5 March 2017; Revised 24 May 2017; Accepted 6 June 2017; Published 27 July 2017

Clinical trials using stem cell therapy for heart diseases have not reproduced the initial positive results obtained with animal models. This might be explained by a decreased regenerative capacity of stem cells collected from the patients. This work aimed at the simultaneous investigation of endothelial stem/progenitor cells (EPCs), mesenchymal stem/progenitor cells (MSCs), and hematopoietic stem/progenitor cells (HSCs) in sternal bone marrow samples of patients with ischemic or valvular heart disease, using flow cytometry and colony assays. The study included 36 patients referred for coronary artery bypass grafting or valve replacement surgery. A decreased frequency of stem cells was observed in both groups of patients. Left ventricular dysfunction, diabetes, and intermediate risk in EuroSCORE and SYNTAX score were associated with lower EPCs frequency, and the use of aspirin and β-blockers correlated with a higher frequency of HSCs and EPCs, respectively. Most importantly, the distribution of frequencies in the three stem cell compartments showed independent patterns. The combined investigation of the three stem cell compartments in patients with cardiovascular diseases showed that they are independently affected by the disease, suggesting the investigation of prognostic factors that may be used to determine when autologous stem cells may be used in cell therapy.

1. Introduction

Cardiovascular disease is one of the major causes of death in the world and requires an extended period of treatment, resulting in high medical costs. Since the first experimental application of stem cell therapy in heart diseases [1], a very large number of preclinical animal studies have shown that stem/progenitor cells have the ability to improve cardiac function and reduce infarct size, in ischemic as well as nonischemic cardiomyopathy [2, 3]. Clinical trials were started very soon after that, using mainly bone marrow-derived stem cells (BMSCs). In spite of reports of effectiveness of cell therapy in heart diseases (reviewed in [4]), the translation of preclinical beneficial results into the clinical setting has been limited. As recently summarized in a systematic review of major randomized controlled cell therapy clinical trials for heart diseases [5], most have proven safe but very limited in clinical efficacy. Despite modest improvements of left ventricular ejection fraction, mortality, reinfarction, or rehospitalization rates were not modified [6]. Many considerations have been made about the most adequate types of stem cells to be used for treating cardiovascular diseases [7]. The most obvious difference between preclinical and clinical studies is the source of stem cells. Preclinical studies generally use young, healthy animals in which the condition to be investigated is experimentally
induced. Stem cells collected from these animals may represent a completely different population in terms of frequency and therapeutic potential, as compared to autologous cells collected from aged patients with heart failure.

A reduction in the function of stem cells frequencies plays a role in tissue ageing and in diseases [8, 9]. A number of studies have shown that risk factors for cardiovascular disease can affect bone marrow progenitor cells, decreasing the ability of regeneration and reducing the effectiveness of cells derived from patients [10, 11]. Attention has also been given to the role of cardiac stem cells (CSCs). The percentage of c-kit + CSCs was shown to be negatively correlated with age, diabetes mellitus, and coronary heart disease [12], and growth properties of these cells have been suggested as a novel biomarker of the outcome of coronary bypass surgery [13].

Three populations of stem and progenitor cells have particular importance for the treatment of cardiovascular disease: endothelial progenitor cells (EPCs) in the bone marrow and peripheral blood, mesenchymal stem cells (MSCs) in the bone marrow and all other tissues and organs, and hematopoietic stem cells (HSCs) in the bone marrow. Although the investigations consistently suggest the presence of a dysfunction of these stem cell compartments in clinical situations, many issues have not yet been clarified. First, although the occurrence of this type of dysfunction in EPCs is described, it has not been consistently investigated for other stem cell types. The role of MSCs in heart disease is particularly relevant, in view of the therapeutic potential of this cell type [14]. Second, some relevant clinical situations have not been explored. And finally, no studies have investigated different types of stem cells in the same patients, in order to evaluate the functional capacity or residual numbers of stem cell compartments and their contribution for the disease. This consideration is particularly important when the source of stem cells to be used in cell therapy procedures is defined [15], since autologous stem cells may not be able to regenerate the injured tissues.

To contribute with this important point, the present study conducted a simultaneous investigation of the frequency of three stem cell compartments—endothelial, hematopoietic, and mesenchymal—in the bone marrow of patients with ischemic or valvular heart disease.

2. Materials and Methods

2.1. Patients. This study included patients referred for coronary artery bypass grafting or valve replacement surgery due to ischemic heart disease (IHD) or nonischemic valvular heart disease (VHD), recruited at Institute of Cardiology of Rio Grande do Sul (RS, Brazil) between May 2011 and June 2012. Exclusion criteria were age lower than 35 years or higher than 70 years, presence of hemato-artery bypass grafting or valve replacement surgery.

May 2011 and June 2012. Exclusion criteria were age lower than 35 years or higher than 70 years, presence of hematologic diseases, cancer, chemotherapy treatment, and previous surgical operation.

Clinical and laboratory data were obtained from medical records, including age, gender, weight (kg), height (m), high blood pressure (defined as use of antihypertensive medication), smoking, diabetes (defined by the use of oral hypoglycemic drugs or insulin), and use of β-blocker, aspirin, or statin. Preoperative hematocrit, hemoglobin, and fasting glucose levels were also included. Kidney function was assessed by determining creatinine clearance with the Cockcroft-Gault equation.

The ejection fraction and left ventricular mass were measured by two-dimensional and Doppler echocardiography. Left ventricular (LV) dysfunction was defined as ejection fraction less than 50% [16] and left ventricular hypertrophy as left ventricular mass index >88 g/m² in women and >102 g/m² in men [17]. The mortality risk was estimated by the logistic EuroSCORE [18], and the SYNTAX score was used to score and grade the coronary lesions [19].

2.2. Isolation and Cultivation of Bone Marrow Mononuclear Cells. Immediately before sternotomy and with the patient under sedation, approximately 20 mL of bone marrow cells was collected by needle puncture of the sternal manubrium anterior wall. Mononuclear cells (MNCs) were isolated by density centrifugation over Ficoll–Paque Plus (GE Healthcare Life Sciences, Piscataway, NJ) for 40 min at 400g, at room temperature. For viability studies, cells were resuspended in RPMI 1640 medium with 100 U/mL penicillin, 0.05 μg/mL streptomycin, and 15% fetal bovine serum (Cultilab, SP, Brazil), and plated onto 96-well plates at 5 × 10⁶ cells/cm². After 1, 3, or 7 days of cultivation, the frequency of viable cells was determined as described above.

All reagents were used from Sigma Chemical Co. (St. Louis, MO), unless otherwise stated. Plasticware was from BD-Brazil (Sao Paulo, Brazil). All cultivations were performed at 37°C in a 5% CO₂ incubator. Cultures were routinely observed with an inverted phase-contrast microscope (Axiovert 25; Zeiss, Hallbergmoos, Germany). Photomicrographs were taken with a digital camera (AxioCamMRc, Zeiss), using AxioVision 3.1 software (Zeiss).

2.3. Analysis of the Endothelial Progenitor Cell Compartment. The EPC compartment in the sternal bone marrow was analyzed by the colony-forming unit (CFU) method [20] and by flow cytometry (below). For the CFU assay, MNCs were resuspended in CFU-Hill medium (StemCell Technologies, Vancouver, Canada), plated on 6-well plates coated with fibronectin (BD-Brazil, SP, Brazil) at a concentration of 5 × 10⁵ cells/cm², and cultured for 48 hours. Nonadherent cells were then collected, resuspended in the same medium, plated in duplicate samples onto fibronectin-coated, 24-wells plates at 5.2 × 10⁵ cells/cm², and cultured for 3 days. After staining with Giemsa, CFU-Hill units, characterized by a central cluster surrounded by elongated cells, were blindly counted and shown as median and interquartile intervals per 10⁶ MNCs.

2.4. Analysis of the Hematopoietic Stem Cell Compartment. The HSC compartment was analyzed by a colony assay using methylcellulose-based culture media with cytokines and by flow cytometry (below). For the colony assay, MNCs were resuspended in Methocult H4034 Optimum medium (StemCell Technologies) and plated onto 6-well plates at 2 × 10⁴ cells/cm². After 14 days, colonies were blindly counted as
2.5. Analysis of the Mesenchymal Stem Cell Compartment.

The MSC compartment was investigated by the colony-forming unit-fibroblast (CFU-F) and by the establishment of conventional MSC cultures, which were then analyzed for immunophenotype and differentiation potential. The CFU-F assay was conducted as previously described [21]. Briefly, MNCs were plated in triplicate samples onto 6-well plates, at $5 \times 10^4$ cells/cm², and cultured for 14 days. After staining with May-Grünwald Giemsa, colonies of ≥30 cells with fibroblastoid morphology were blindly counted and shown as median and interquartile intervals per 10⁵ MNCs.

To establish MSC cultures, MNCs were resuspended in Dulbecco’s modified Eagle’s medium (DMEM) with HEPES, 50 U/mL penicillin, 0.05 μg/mL streptomycin, and 15% fetal bovine serum (Cultilab) and plated onto 12-well plates at $2 \times 10^5$ cells/cm². Three days later, nonadherent cells were removed. For subculture, the adherent layer was incubated with 0.25% trypsin and 0.01% EDTA and split at ratios empirically determined for two subcultures a week. Cultures were considered successful when reaching the third passage (P3). The plasticity of MSCs was analyzed by incubating P3 or P4 cultures with adipogenic or osteogenic medium as described [22]. Differentiated cells were identified by staining with Oil Red O or Alizarin red, respectively. Cultures were immunophenotyped by flow cytometry (below).

2.6. Flow Cytometry. For analysis of the frequency of EPCs and HSCs by flow cytometry in fresh bone marrow samples, 10⁵ MNCs were incubated for 15 min with antibodies specific for CD34 and KDR or CD34 and CD38 (BD-Brazil), respectively. The anti-CD34 antibody was conjugated to phycoerythrin, and the other two antibodies to fluorescein isothiocyanate. After washing for removal of excess antibodies, the cells were analyzed using a FACScalibur cytometer equipped with 488 nm argon laser (Becton Dickinson, San Diego, CA) with the CellQuest software. At least 100,000 events in the lymphocyte gate were collected.

For immunophenotyping of MSCs, P3 or P4 cultures were trypsinized, washed, and incubated for 15 min with specific antibodies for CD34, CD45, CD14, CD90, CD105, CD73, and HLA-DR (BD-Brazil), conjugated to phycoerythrin or fluorescein isothiocyanate. The cells were analyzed in a FACScalibur flow cytometer as above, and 10,000 events were collected.

2.7. Statistical Analysis. Statistical analyses were performed with the SPSS software package, version 19.0, and GraphPad Prism 5. Numeric variables are described as mean and standard deviation or median and interquartile range (25–75%). Categorical variables are described as proportions. Categorical variables were analyzed with the Chi-square test, and numeric variables with Student’s t-test and the Mann–Whitney test. Correlations were analyzed with the Pearson correlation coefficient. A p value of <0.05 was considered statistically significant for all comparisons.

3. Results

3.1. Patient Population. The population studied included 20 patients with IHD and 16 with VHD. As presented in Table 1, mean age was similar in the two groups; there were no significant differences observed in gender or ejection fraction, but the body mass index was lower in IHD patients. Furthermore, a higher use of β-blockers, aspirin, and statins was also observed in IHD patients.

Patients were also classified according to the presence or absence of LV dysfunction, with no differences in baseline characteristics (Table 1).

3.2. Isolation and Viability of Sternal Bone Marrow Mononuclear Cells. The mean volume of the sternal bone marrow collected was $20 \pm 3$ mL, which yielded in average $2.5 \pm 1.8 \times 10^6$ cells/mL of tissue without significant correlation between MNC concentration and bone marrow aspiration volume (Figure 1(a)). There was however a significant inverse correlation between MNC concentration and age of patients (Figure 1(b)).

The cells were cultured on fibronectin-coated plates, and the viability of adherent and nonadherent cells, evaluated on days 1, 3, and 7, was always higher than 90% (not shown). Some of the samples could not be analyzed by all of the methods employed in this study, mainly for technical reasons.

3.3. Endothelial Progenitor Cell Compartment. CFU-Hill colonies presented the typical morphology of a central cell cluster surrounded by emerging cells (Figure 2(a)), and a good correlation was observed between the colony assay and flow cytometry in determining EPC frequencies (Figure 2(b)). The number of colonies/well showed great variation, but the difference was not statistically significant (Table 2). However, a significantly lower clonogenic potential was observed in samples from patients with LV dysfunction (Table 2). Determination of the frequency of EPCs by flow cytometry (CD34⁺KDR⁺ cells) had a good correlation with the colony assay (Figure 2(b)) and showed similar results in all groups of patients (Table 2).

The cells used in the EPC colony assay were also evaluated for viability, when nonadherent cells were replated on day 2. Similar results were observed in the two groups of samples, with over 99% viability ($p = 0.957$) (not shown).

3.4. Hematopoietic Stem Cell Compartment. The HSC compartment was analyzed with a colony assay which allowed the identification of different types of precursors in the bone marrow mononuclear fraction (Figures 3(a), 3(b), and 3(c)). As presented in Table 2, IHD samples had in general higher numbers of the three types of colonies, as well as for the total number of colonies, but the differences were not statistically significant. Flow cytometry results for CD34⁺CD38⁻ cell frequency had a good correlation with the colony assay (Figure 3(d)), and although much less variable showed similar results between IHD and VHD patients.
Results were similar for patients with or without LV dysfunction.

3.5. Mesenchymal Stem Cell Compartment. The CFU-F assay showed a very low frequency of mesenchymal stem cells in samples from both groups of patients (Table 2). Among the 15 samples from IHD patients, in only one case (7%) the culture was established. For VHD samples, two cases among 14 MSC cultures (14%) were successful. These cultures presented the characteristic fibroblastoid morphology of mesenchymal stem cells (Figure 4(a)). Immunophenotyping of MSC cultures showed low or no expression of hematopoietic markers (CD34, CD14, CD45) and HLA-DR and presence of CD73, CD90, and CD105 (Figure 4(b)). After three weeks in culture with differentiation-inducing media, all MSC cultures differentiated into adipocytes or osteocytes (Figures 4(c), 4(d), and 4(f)).

3.6. Distribution of Frequencies of the Stem Cell Compartments. The results of the three colony assays were individually compared in the 20 patients for whom the complete results were available. As shown in Figure 5, in only five cases, the frequency of stem cells from the three compartments is above \((n = 1)\) or below \((n = 4)\) the median. In all other samples, the distribution of frequencies of stem cells is placed above or below the median line in a variable

### Table 1: Baseline characteristics of the study population.

| Characteristics     | Heart disease IHD \((n = 20)\) | LV dysfunction Presence \((n = 17)\) | LV dysfunction Absence \((n = 19)\) |
|---------------------|---------------------------------|-------------------------------------|-------------------------------------|
| Age (years)         | 61.0 ± 8.5                      | 63 ± 8.7                             | 59 ± 9.4                             |
| Male \((n)\)        | 15                              | 14                                  | 11                                  |
| BMI (kg/m²)         | 26.2 ± 2.8                      | 27 ± 6.3                             | 25 ± 3.1                             |
| Hypertension (%)    | 94.4                            | 88                                  | 80                                  |
| Smoking (%)         | 66.7                            | 55                                  | 45                                  |
| Diabetes (%)        | 80                              | 83                                  | 75                                  |
| LV EF (%)           | 55.6 ± 13.7                     | 43 ± 4.3                             | 67 ± 6.5                             |
| LV mass             | 110 ± 30.16                     | 140 ± 26.1                           | 104 ± 22.2                           |
| Hypertrophy \((n)\) | 11                              | 13                                  | 8                                   |
| β-blockers (%)      | 90                              | <0.001                              | 63                                  |
| Aspirin (%)         | 90                              | <0.001                              | 63                                  |
| Statins (%)         | 85                              | 82                                  | 73                                  |
| Hematocrit (%)      | 38.6 ± 6.6                      | 38 ± 5.8                             | 39.2 ± 5.7                           |
| Hemoglobin (g/dL)   | 12.7 ± 2.1                      | 12.4 ± 1.9                           | 12.8 ± 1.9                           |
| Leukocytes \(×10³/μL\) | 9.6 ± 3.9                      | 7.9 ± 3.1                            | 6.7 ± 2.5                            |
| Glucose (mg/dL)     | 133.6 ± 36.4                    | 129.8 ± 49.8                         | 138.7 ± 50.1                         |
| Creatinine (mg/dL)  | 1.0 ± 0.4                       | 1.02 ± 0.4                           | 1.07 ± 0.3                           |
| Sodium (mEq/L)      | 137.9 ± 3.6                     | 138.5 ± 3.38                         | 138.1 ± 2.99                         |
| Potassium (mEq/L)   | 4.4 ± 0.5                       | 4.42 ± 0.4                           | 4.31 ± 0.5                           |

BMI: body mass index; EV: ejection fraction; IHD: ischemic heart disease; LV: left ventricular; VHD: vascular heart disease. The results are presented as mean and standard deviation or median and interquartile range. *p value, Student’s t-test and chi-square test.

![Figure 1](image_url)  
**Figure 1**: Relationship between the concentration of mononuclear cells and mean volume of the sternal bone marrow collected (a) and age of patients (b).

(Table 2). Results were similar for patients with or without LV dysfunction.
3.7. LV Dysfunction and Cardiovascular Risk Factors versus Stem Cell Compartments.

The frequency and function of stem cells from the sternal bone marrow was analyzed according to presence of LV dysfunction, diabetes, and smoking and age greater than 65 years. The number of isolated cells was significantly higher for age below 65 years (Figure 6(a)). Similar frequencies of MSCs were observed in all groups (Figure 6(b)). The clonogenic potential of EPCs was lower in samples from older patients and in the presence of cardiovascular risks, but statistical significance was observed only in the presence of LV dysfunction and diabetes (Figure 6(c)). Their frequency as assessed by flow cytometry was similar for all groups (Figure 6(d)). For HSCs, similar clonogenic (Figure 6(e)) and flow cytometry (Figure 6(f)) results were observed, except for a higher clonogenic potential in samples from smoking patients.

A simple logistic regression model was used to identify clinical and laboratory characteristics potentially affecting the frequency and function of EPCs and HSCs in sternal bone marrow samples. The characteristics evaluated were age, body mass index, smoking, renal disease, myocardial hypertrophy, LV dysfunction, use of medications, anemia, and fasting glucose level. The following associations were observed (Figure 7): lower clonogenic potential for EPCs and LV dysfunction (OR = 8.8; 95% CI = 1.69–45.78; p = 0.006), increased frequency of CD34+KDR+ cells and use of aspirin (OR = 0.02; 95% CI = 0.00–0.09; p = 0.02), lower clonogenic potential for HSCs and hemoglobin level <12 g/dL. (OR = 6.2; 95% CI = 1.5–36.21; p = 0.030), and increased frequency of CD34+CD38− cells and use of β-blockers (OR = 0.16; 95% CI = 0.02–0.80; p = 0.043). The frequency and function of MSCs could not be analyzed with pattern, considering the characteristics analyzed in the population of patients.

Table 2: Frequency of endothelial progenitor cells, hematopoietic stem cells, and mesenchymal stem cells in the sternal bone marrow samples from patients with ischemic or valvular heart disease, in presence or absence of left ventricular dysfunction. Cells were analyzed by colony assay (CFU) and flow cytometry (FACS).

| Cell population (assay) | Heart disease (n = 20) | LV dysfunction (n = 16) | p* | Heart disease (n = 17) | LV dysfunction (n = 19) | p* |
|-------------------------|------------------------|------------------------|----|------------------------|------------------------|----|
|                         | IHD (n = 20)           | VHD (n = 16)           |     | Presence (n = 17)      | Absence (n = 19)       |     |
| EPCs (CFU)              | 1.9 (0.0–6.5)          | 0.6 (0.0–7.5)          | 0.675 | 1 (0–11)               | 18 (4–44)              | 0.038 |
| EPCs (FACS)             | 174.1 ± 40.2           | 182.7 ± 51.7           | 0.611 | 171 ± 43.4             | 187 ± 45.6             | 0.341 |
| HSCs (CFU)              | 6.5 (1–23)             | 1 (0–19)               | 0.411 | 21 (1–44)              | 9 (0–48)               | 0.727 |
| BFU-E                   | 22 (6–46)              | 15.5 (2–46)            | 0.710 | 45 (9–95)              | 44 (7–94)              | 0.960 |
| HSC-GEMM                | 54 (14–86)             | 18 (1–91)              | 0.313 | 67 (5–172)             | 76 (7–266)             | 0.881 |
| HSCs (CFU)—total colonies | 86 (22–154)           | 48 (5–144)             | 0.520 | 93 (14–309)            | 167 (13–322)           | 0.855 |
| HSCs (FACS)             | 19.7 ± 6.6             | 17.6 ± 4.6             | 0.347 | 19.5 ± 6.3             | 17.9 ± 5.4             | 0.442 |
| MSCs (CFU)              | 0.6 (0.3–0.9)          | 0.2 (0–0.7)            | 0.400 | 1 (1–1.5)              | 3 (1–6)                | 0.308 |

BFU-E: erythroid burst-forming units; CFU-GM: colony-forming units-granulocyte/macrophage; CFU-GEMM: multipotent myeloid stem cells; EPCs: endothelial progenitor cells; EV: ejection fraction; HSCs: hematopoietic stem cells; IHD: ischemic heart disease; LV: left ventricular; MSCs: mesenchymal stem cells; VHD: vascular heart disease. The results are presented as mean and standard deviation, or median and interquartile range. *p value, Student’s t-test and chi-square or Mann–Whitney test.
this model, due to the low frequency of this cell population in the samples.

An increased frequency of CD34°KDR+ cells was observed in samples from low-risk patients in both the EuroSCORE and the SYNTAX score, and a higher frequency of CD34+CD38− cells was seen in samples from low-risk patients according to the SYNTAX score (Table 3).

4. Discussion

This study characterized stem cell compartments in the bone marrow of patients with ischemic or valvular heart disease. The sample included mostly elderly patients with cardiovascular risk factors such as obesity, hypertension, smoking, and diabetes. The groups with ischemic or valvular heart diseases showed similar clinical and laboratory characteristics, differing mainly in features such as the BMI and the use of medications including β-blockers, aspirin, and statins used as a preventive measure of cardiovascular events for patients with ischemic heart disease [23].

The MSC compartment showed extremely low cell frequencies in the two types of heart diseases, and successful cultures could be established only from one IHD sample and two VHD samples. These cultures were evaluated for immunophenotype and osteogenic/adipogenic differentiation, showing features typical of MSCs as proposed by the International Society for Cellular Therapy [24]. The methods for isolating and cultivating MSC are very well established and have been used by our group for over 10 years for murine [21, 25], rat [26], canine [27], and human [28, 29] bone marrow- and adipose tissue-derived cells. Therefore, the difficulty in establishing MSC cultures should be explained by intrinsic characteristics of the sample, such as old age and disease.

In the present study, the frequencies of MSCs obtained from sternal bone marrow samples from patients with IHD and VHD were, respectively, 0.6 and 0.2 CFU-F/10^6 MNCs, significantly lower than those found in younger, normal individuals [30, 31]. Similar results were recently described by Neef et al., who observed a frequency of 5.5 colonies/10^6 MNCs in a group of patients undergoing elective cardiac surgery, with mean age of 68 years [10]. A decline in the number of CFU-F with the advancement of age has been previously reported, with CFU-F values around four times lower in 21–40-year-old bone marrow donors than in 0–20-year-old donors [32]. MSC cultures established from bone marrow samples from healthy children show high proliferative
potential, rapid growth, and better clonogenic potential as compared to bone marrow samples from healthy adults [33]. Similarly, heart disease and other pathological conditions have been shown to decrease MSC frequencies [8, 34]. Animal studies have also shown a decrease in the proliferative potential of MSCs with age [35].
Cell frequencies in the EPC compartments were also similar in the two groups of patients, as shown by flow cytometry and colony assay. A correlation was observed between the number of CFU and the number of CD34\(^+\)KDR\(^+\) cells assessed by flow cytometry in samples from cardiac patients. In contrast, George et al. [36] did not observe a correlation between the number of EPCs measured by the colony assay and flow cytometry in the peripheral blood of healthy individuals, suggesting that the flow cytometry is more suitable to define the frequency of circulating EPCs, while the number of CFU would reflect their proliferative ability.

In bone marrow samples from healthy donors, the frequency of CD34\(^+\)KDR\(^+\) cells was reported as 5.43% [37], much higher than the frequencies observed in the present study. We also observed a lower clonogenic potential for the EPC compartment in samples from both groups of patients than that reported for normal bone marrow donors [37].

In our study, the frequency of HSCs was similar in samples from both groups of patients. The frequency of CD34\(^-\)CD38\(^-\) cells observed in IHD and VHD samples was lower than the frequency reported in bone marrow samples from healthy individuals [38], showing that the hematopoietic stem cell compartment is also affected in heart disease patients. The colony assay also showed low numbers of HSCs in the present study, as compared to values in healthy younger individuals [39]. In a comparison of samples from heart disease patients and healthy controls, lower numbers of CFU-GM were observed in the first group [40]. Function, besides frequency, may be affected by age and disease. The migratory response and clonogenic potential of bone marrow-derived circulating progenitor cells were shown to be impaired in patients with cardiovascular disease, suggesting that the mobilization and homing of stem cells may be also affected by heart disease [41].

The characteristics of these three cell populations in the iliac crest bone marrow are well known, but few studies have compared cells isolated from different sites, particularly the sternum. MSCs isolated from the equine sternum and ilium showed similar characteristics [42, 43], but a significantly faster proliferation rate has been reported for sternal than for ilial cells [44]. In sheep, the sternum was considered as an equally good source of bone marrow MSCs, with cell division cycle and proliferative potential similar to the cells from the iliac bones [45]. Human MSCs isolated from the iliac crest, sternum, and vertebrae bone marrow have also shown similar immunophenotype but different growth/differentiation potentials and homeobox gene expression, suggesting that they do not represent equivalent cell sources for therapeutic applications [46]. Gradual loss of ability to proliferate and a morphological conversion of senescence tendency have also been reported for human sternal MSCs [47].

EPCs have been mainly analyzed as circulating cells, due to the association between this variable and cardiovascular risk [48], and are more frequent in the bone marrow than in nonmobilized cytapheresis peripheral blood [49]. For HSCs, initial studies showed that the concentration of CFUs in murine sternal marrow is about 40% less than in the marrow of lumbar vertebrae and femora [50]. The comparison cord blood, bone marrow, and peripheral blood have shown significant differences in mean cell density values [51], as well as gene and miRNA expression profiles [52, 53], suggesting diversity in biological processes such as cell cycle regulation and cell motility.

Many of the risk factors for cardiovascular disease are well established, and their effect on stem cell compartments has been shown [12, 13]. The present results, showing that the number of mononuclear cells isolated from the bone marrow is lower in patients older than 65 years, support previous studies on bone marrow ageing [11] and its relationship with a decrease in the frequency of MSCs [32], HSCs [54], and EPCs [48]. A relationship was also observed between diabetes and lower frequency and clonogenic potential of EPCs, as already described [55], showing the prejudicial impact of this pathology on the endothelial precursor cell compartment. An interesting result was the higher clonogenic potential of HSCs in samples from...
smoking patients, since smoking is a well-established risk factor for cardiovascular disease. Similar results have been previously reported in an animal study [56], which however showed no increase in cellular function.

The SYNTAX score was developed to quantify the complexity of coronary lesions and is used to guide treatment of patients with ischemic heart disease [57]. The score can also be used to predict long-term major cardiovascular events after revascularization [58]. In our study, patients with a higher SYNTAX score, which is an indicative of higher atherosclerotic burden and more severe ischemic heart disease, had a lower number of CD34^+KDR^+ and CD34^+CD38^- cells.

The present study has some limitations, such as a relatively small sample and the lack of a control group matched for age. The problem of a control group is very difficult to solve in this kind of study: the bone marrow from healthy donors is not adequate, and ethical reasons do not allow sternal bone marrow collection from aged cardiac patients or healthy volunteers. Nevertheless, our

---

**Figure 6:** Effect of LV dysfunction (LVD) and cardiovascular risk factors (age over 65 years, diabetes mellitus, and smoking) on bone marrow stem cell compartments. (a) Number of mononuclear cells isolated from the sternal bone marrow. Results of clonogenic assay (CFU) and flow cytometry analyses (FACS) of mesenchymal stem cells (MSCs, (b)), endothelial progenitor cells (EPCs, (c), (d)), and hematopoietic stem cells (HSCs, (e), (f)). Student's t-test and Mann–Whitney test. DM: Diabetes mellitus. + or −: presence or absence.
results support previous reports showing decreased frequencies of stem cells in aged, diseased individuals [59] and presents in a more comprehensive manner the concept of how age and disease may affect stem cell compartments. To our knowledge, this is the first time that different types of stem cell compartments are analyzed in patients with cardiovascular diseases, which has made it possible to observe that they are simultaneously, but independently affected by age and disease. Although all three types of stem cells presented lower frequencies than those reported in the literature for young, normal individuals, a large variation was observed among them, and the compartments distributed above or below the median frequency in an independent manner. This suggests that the MSC, HSC, and EPC compartments are independently affected in aged patients with heart disease.

The use of allogeneic mesenchymal stem cells has already been proven safe in patients with myocardial infarction [60, 61]. Our results added to other studies showing quantitative and functional limitations of stem cell compartments in aged patients with heart disease. Further clinical studies using allogeneic, cultured mesenchymal stem cells from healthy donors, feasible due to their immunoregulatory properties [62], should establish their therapeutic potential in heart failure.

**Disclosure**

The results were partially presented as an abstract at the ASCB Annual Meeting 2013 (Mol Biol Cell. 2013; 24;1176).

**Conflicts of Interest**

The authors declare that there is no conflict of interest regarding the publication of this paper.
Acknowledgments

The authors gratefully acknowledge Paula Nesralla, Álvaro Albrecht, Alexandra Balbinot, Daniel Schoeder, Melissa Kristocheck da Silva, and Vitor Magnus Martins for collecting the sternal bone marrow samples used in this study. This work was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), and Fundo de Apoio do Instituto de Cardiologia/FUC à Ciência e Cultura (FAPICCC).

References

[1] D. Orlic, J. Kajstura, S. Chimenti et al., “Bone marrow cells regenerate infarcted myocardium,” Nature, vol. 410, no. 6829, pp. 701–705, 2001.
[2] S. K. Sanganalmath and R. Bolli, “Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions,” Circulation Research, vol. 113, no. 6, pp. 810–834, 2013.
[3] J. Kim, L. Shapiro, and A. Flynn, “The clinical application of mesenchymal stem cells and cardiac stem cells as a therapy for cardiovascular disease,” Pharmacology & Therapeutics, vol. 151, pp. 8–15, 2015.
[4] S. A. Fisher, C. Doree, A. Mathur, D. P. Taggart, and E. Martin-Rendon, “Stem cell therapy for chronic ischaemic heart disease and congestive heart failure,” Cochrane Database of Systematic Reviews, vol. 12, article CD007888, 2016.
[5] P. K. Nguyen, J. W. Rhee, and J. C. Wu, “Adult stem cell therapy and heart failure, 2000 to 2016: a systematic review,” JAMA Cardiology, vol. 1, no. 7, pp. 831–841, 2016.
[6] O. Pfister, G. Della Verde, R. Liao, and G. M. Kuster, “Regenerative therapy for cardiovascular disease,” Translational Research, vol. 163, no. 4, pp. 307–320, 2014.
[7] S. Musa, L. Z. Xin, V. Govindasamy, F. W. Fuen, and N. H. Kasim, “Global search for right cell type as a treatment modality for cardiovascular disease,” Expert Opinion on Biological Therapy, vol. 14, no. 1, pp. 63–73, 2014.
[8] Y. Li, N. Charif, D. Mainard, D. Bensoussan, J. F. Stoltz, and N. de Isla, “Donor’s age dependent proliferation decrease of human bone marrow mesenchymal stem cells is linked to diminished clonogenicity,” Bio-Medical Materials and Engineering, vol. 24, Supplement 1, pp. 47–52, 2014.
[9] E. Rurali, B. Bassetti, G. L. Perrucchi et al., “BM ageing: implication for cell therapy with EPCs,” Mechanisms of Ageing and Development, vol. 159, pp. 4–13, 2016.
[10] K. Neef, Y. H. Choi, A. Weichel et al., “The influence of cardiovascular risk factors on bone marrow mesenchymal stromal cell fitness,” Cytotherapy, vol. 14, no. 6, pp. 670–678, 2012.
[11] A. R. Mendelsohn and J. W. Larrick, “Rejuvenation of adult stem cells: is age-associated dysfunction epigenetic?,” Rejuvenation Research, vol. 16, no. 2, pp. 152–157, 2013.
[12] S. Hu, G. Yan, W. He, Z. Liu, H. Xu, and G. Ma, “The influence of disease and age on human cardiac stem cells,” Annals of Clinical Biochemistry, vol. 51, Part 5, pp. 582–590, 2014.
[13] D. D’Amario, A. M. Leone, A. Iaconelli et al., “Growth properties of cardiac stem cells are a novel biomarker of patients’ outcome after coronary bypass surgery,” Circulation, vol. 129, no. 2, pp. 157–172, 2014.
[14] L. S. Meirelles and N. B. Nardi, “Methodology, biology and clinical applications of mesenchymal stem cells,” Frontiers in bioscience (Landmark edition), vol. 14, pp. 4281–4298, 2009.
[15] M. A. Deutsch, A. Sturzu, and S. M. Wu, “At a crossroad: cell therapy for cardiac repair,” Circulation Research, vol. 112, no. 6, pp. 884–890, 2013.
[16] J. J. McMurray, S. Adamopoulos, S. D. Anker et al., “ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC,” European Journal of Heart Failure, vol. 14, no. 8, pp. 803–869, 2012.
[17] R. M. Lang, M. Bierig, R. B. Devereux et al., “Recommendations for chamber quantification: a report from the American Society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology,” Journal of the American Society of Echocardiography, vol. 18, no. 12, pp. 1440–1463, 2005.
[18] S. A. Nashel, F. Roques, P. Michel, E. Gauducheau, S. Lemeshow, and R. Salamon, “European system for cardiac operative risk evaluation (EuroSCORE),” European Journal of Cardio-Thoracic Surgery, vol. 16, no. 1, pp. 9–13, 1999.
[19] P. W. Serruys, Y. Onuma, S. Garg et al., “Assessment of the SYNTAX score in the Syntax study,” EuroIntervention, vol. 5, no. 1, pp. 50–56, 2009.
[20] J. M. Hill, G. Zalos, J. P. Halcox et al., “Circulating endothelial progenitor cells, vascular function, and cardiovascular risk,” The New England Journal of Medicine, vol. 348, no. 7, pp. 593–600, 2003.
[21] M. L. da Silva, P. C. Chagastelles, and N. B. Nardi, “Mesenchymal stem cells reside in virtually all post-natal organs and tissues,” Journal of Cell Science, vol. 119, Part 11, pp. 2204–2213, 2006.
[22] L. F. Diesel, B. P. dos Santos, B. C. Bellagamba et al., “Stability of reference genes during tri-lineage differentiation of human adipose-derivedstromal cells,” Journal of Stem Cells, vol. 10, no. 4, pp. 225–242, 2015.
[23] S. C. Smith, E. J. Benjamin, R. O. Bonow et al., “AHA/ACC/F/CA secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association,” Journal of the American College of Cardiology, vol. 58, no. 23, pp. 2432–2446, 2011.
[24] M. Dominici, K. Le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” Cytotherapy, vol. 8, no. 4, pp. 315–317, 2006.
[25] L. S. Metrelles and N. B. Nardi, “Murine marrow-derived mesenchymal stem cell: isolation, in vitro expansion, and characterization,” British Journal of Haematology, vol. 123, no. 4, pp. 702–711, 2003.
[26] L. M. de Macedo Braga, S. Lacchini, B. D. Schaan et al., “In situ delivery of bone marrow cells and mesenchymal stem cells improves cardiovascular function in hypertensive rats submitted to myocardial infarction,” Journal of Biomedical Science, vol. 15, no. 3, pp. 365–374, 2008.
[27] C. Marx, M. D. Silveira, I. Selbach et al., "Acupoint injection of autologous stromal vascular fraction and allogeneic adipose-derived stem cells to treat hip dysplasia in dogs," Stem Cells International, vol. 2014, Article ID 391274, 6 pages, 2014.
[28] N. Ahmadbeigi, M. Soleimani, F. Babaeijandaghi et al., "The aggregate nature of human mesenchymal stromal cells in native bone marrow," Cytotherapy, vol. 14, no. 8, pp. 917–924, 2012.
[29] C. F. Markarian, G. Z. Frey, M. D. Silveira et al., "Stem Cells International, vol. 36, no. 4, pp. 693–702, 2014.
[30] C. Bacelli-Tyndall, L. Bracci, G. Spagnoli et al., "Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro," Rheumatology (Oxford, England), vol. 46, no. 3, pp. 403–408, 2007.
[31] H. Castro-Malaspina, R. E. Gay, G. Resnick et al., "Characterization of human bone marrow fi broblast colony-forming cells (CFU-F) and their progeny," Blood, vol. 56, no. 2, pp. 289–301, 1980.
[32] A. Stolzing, E. Jones, D. McGonagle, and A. Scutt, "Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies," Mechanisms of Ageing and Development, vol. 129, no. 3, pp. 163–173, 2008.
[33] D. M. Choumerianou, G. Martimianaki, E. Stiakaki, L. Kalmanti, M. Kalmanti, and H. Dimitriou, "Comparative study of stemness characteristics of mesenchymal cells from bone marrow of children and adults," Cytotherapy, vol. 12, no. 7, pp. 881–887, 2010.
[34] K. Kornicka, K. Marycz, K. A. Tomaszewski, M. Mar, and A. Smieszek, "The effect of age on osteogenic and adipogenic differentiation potential of human adipose derived stromal stem cells (hASCs) and the impact of stress factors in the course of the differentiation process," Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 309169, 20 pages, 2015.
[35] J. D. Kretlow, Y. Q. Jin, W. Liu et al., "Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells," BMC Cell Biology, vol. 9, p. 60, 2008.
[36] J. George, H. Shmilovich, V. Deutsch, H. Miller, G. Keren, and A. Roth, "Comparative analysis of methods for assessment of circulating endothelial progenitor cells," Tissue Engineering, vol. 12, no. 2, pp. 331–335, 2006.
[37] O. Tura, G. R. Barclay, H. Roddie, J. Davies, and M. L. Turner, "Absence of a relationship between immunophenotypic and colony enumeration analysis of endothelial progenitor cells in clinical haematopoietic cell sources," Journal of Translational Medicine, vol. 5, p. 37, 2007.
[38] Q. L. Hao, A. J. Shah, F. T. Thiemann, E. M. Smogorzewska, and G. M. Crooks, "A functional comparison of CD34+CD38- cells in cord blood and bone marrow," Blood, vol. 86, no. 10, pp. 3745–3753, 1995.
[39] F. Lanza, D. Campioni, M. Punturieri et al., "In vitro assessment of bone marrow endothelial colonies (CFU-En) in non-Hodgkin’s lymphoma patients undergoing peripheral blood stem cell transplantation," Bone Marrow Transplantation, vol. 32, no. 12, pp. 1165–1173, 2003.
[40] C. Heeschen, R. Lehmann, J. Honold et al., "Profoundly reduced neovascularization capacity of bone marrow mononuclear cells derived from patients with chronic ischemic heart disease," Circulation, vol. 109, no. 13, pp. 1615–1622, 2004.
[41] I. Bozdağ-Turan, R. G. Turan, L. Paranskaya et al., "Correlation between the functional impairment of bone marrow-derived circulating progenitor cells and the extend of coronary artery disease," Journal of Translational Medicine, vol. 10, p. 143, 2012.
[42] M. K. Adams, L. R. Goodrich, S. Rao et al., "Equine bone marrow-derived mesenchymal stromal cells (BMDMScs) from the ilium and sternum: are there differences?," Equine Veterinary Journal, vol. 45, no. 3, pp. 372–375, 2013.
[43] J. D. Kisiday, L. R. Goodrich, C. W. McIlwraith, and D. D. Frisbie, "Effects of equine bone marrow aspirate volume on isolation, proliferation, and differentiation potential of mesenchymal stem cells," American Journal of Veterinary Research, vol. 74, no. 5, pp. 801–807, 2013.
[44] U. Delling, K. Lindner, I. Ribitsch, H. Jülke, and W. Brehm, "Comparison of bone marrow aspiration at the sternum and the tibial coxae in middle-aged horses," Canadian Journal of Veterinary Research, vol. 76, no. 1, pp. 52–56, 2012.
[45] G. J. Harker, R. A. Zbroja, J. Wass, P. C. Vincent, and F. O. Stephens, "Cell cycle homogeneity in bone marrow samples from different sites: flow cytometric evaluation of multiple samples from sheep," Experimental Hematology, vol. 11, no. 10, pp. 1037–1041, 1983.
[46] J. Picchi, L. Trombi, L. Spugnesi et al., "HOX and TALE signatures specify human sternal stem cell populations from different sources," Journal of Cellular Physiology, vol. 228, no. 4, pp. 879–889, 2013.
[47] C. P. Hsu, J. S. Wang, S. C. Hung, S. T. Lai, Z. C. Weng, and R. C. J. Chiu, "Human sternal mesenchymal stem cells: isolation, characterization and cardiomyogenic differentiation," Acta Cardiologica Sinica, vol. 26, pp. 242–252, 2010.
[48] L. Koller, P. Hohensinner, P. Sulzgruber et al., "Prognostic relevance of circulating endothelial progenitor cells in patients with chronic heart failure," Thrombosis and Haemostasis, vol. 110, no. 2, pp. 309–316, 2016.
[49] C. Tournois, B. Pignon, M. A. Sevestre et al., "Cell therapy in critical limb ischemia: a comprehensive analysis of two cell therapy products," Cytotherapy, vol. 19, no. 2, pp. 299–310, 2017.
[50] G. E. Schoeters and O. L. Vanderbilt, "Haemopoietic stem cell concentration and CFUs in DNA synthesis in bone marrow from different bone regions," Experientia, vol. 36, no. 4, pp. 459–461, 1980.
[51] A. B. Araújo, M. H. Angeli, G. D. Salton, J. M. Furlan, T. Costa, and C. F. Markarian, "Unique biological properties and application potentials of CD34+CD38- stem cells from various sources," Taiwanese Journal of Obstetrics & Gynecology, vol. 48, no. 4, pp. 356–369, 2009.
[52] A. Báez, B. Martin-Antonio, J. I. Piruat et al., "Gene and miRNA expression profiles of hematopoietic progenitor cells vary depending on their origin," Biology of Blood and Marrow Transplantation, vol. 20, no. 5, pp. 630–639, 2014.
K. S. Cohen, S. Cheng, M. G. Larson et al., “Circulating CD34(+) progenitor cell frequency is associated with clinical and genetic factors,” *Blood*, vol. 121, no. 8, pp. e50–e56, 2013.

O. M. Tepper, R. D. Galiano, J. M. Capla et al., “Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures,” *Circulation*, vol. 106, no. 22, pp. 2781–2786, 2002.

E. Chang, E. C. Forsberg, J. Wu et al., “Cholinergic activation of hematopoietic stem cells: role in tobacco-related disease?,” *Vascular Medicine*, vol. 15, no. 5, pp. 375–385, 2010.

S. Windecker, P. Kolh, F. Alfonso et al., “2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI),” *European Heart Journal*, vol. 35, no. 37, pp. 2541–2619, 2014.

F. W. Mohr, M. C. Morice, A. P. Kappetein et al., “Coronary artery bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial,” *Lancet*, vol. 381, no. 9867, pp. 629–638, 2013.

P. Goichberg, R. Kannappan, M. Cimini et al., “Age-associated defects in EphA2 signaling impair the migration of human cardiac progenitor cells,” *Circulation*, vol. 128, no. 20, pp. 2211–2223, 2013.

J. M. Hare, J. H. Traverse, T. D. Henry et al., “A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction,” *Journal of the American College of Cardiology*, vol. 54, no. 24, pp. 2277–2286, 2009.

V. Y. Suncion, E. Ghersin, J. E. Fishman et al., “Does transendocardial injection of mesenchymal stem cells improve myocardial function locally or globally?: an analysis from the percutaneous stem cell injection delivery effects on neomyogenesis (POSEIDON) randomized trial,” *Circulation Research*, vol. 114, no. 8, pp. 1292–1301, 2014.

K. Le Blanc, C. Tammik, K. Rosendahl, E. Zetterberg, and O. Ringdén, “HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells,” *Experimental Hematology*, vol. 31, no. 10, pp. 890–896, 2003.